For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
Extracellular domain of Human EGF-receptor from head and neck carcinoma
Our Abpromise guarantee covers the use of ab231 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Inhibition Assay||Use at an assay dependent concentration. See ELISA Abreview.|
|Flow Cyt||1/50 - 1/100.
ab18450 - Rat monoclonal IgG2a, is suitable for use as an isotype control with this antibody.
|ELISA||Use at an assay dependent concentration.|
|IP||Use at an assay dependent concentration.|
|IHC-Fr||Use at an assay dependent concentration.|
|ICC||Use at an assay dependent concentration.|
ICC/IF image of ab231 stained human HeLa cells. The cells were methanol fixed (5 min) and incubated with the antibody (ab231, 5µg/ml) for 1h at room temperature. The secondary antibody (green) was Alexa Fluor® 488 donkey anti-rat IgG (H+L) used at a 1/1000 dilution for 1h. Image-iTTM FX Signal Enhancer was used as the primary blocking agent, 5% BSA (in TBS-T) was used for all other blocking steps. DAPI was used to stain the cell nuclei (blue). Alexa Fluor® 594 WGA was used to label plasma membranes (red).
ab231 used undiluted in inhibition assay against human recombinant protein EGFR1:Fc to inhibit binding to EGF:Biotin. The primary incubated with sample for 1 hour. The antibody inhibits the binding of biotinylated EGF to coated EGFR:Fc with an IC50 ~ 5 nM.